Evozyne has filed a notice of an exempt offering of securities to raise $100,000,001.00 in New Equity and Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, Evozyne is raising $100,000,001.00 in new funding. Sources indicate that as part of senior management Senior Executive, Jeffrey Aronin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Evozyne
Evozyne combines evolution and deep learning technology to create highly functional novel proteins Natural Machines to solve longstanding challenges in therapeutics and sustainability. By amplifying a proteins function based on the rules of nature, we address complex, high-impact problems. From developing life-changing patient treatments to making carbon capture a reality, Evozyne is committed to making a healthier, more sustainable world.
To learn more about Evozyne, visit http://evozyne.com/
Contact:
Jeffrey Aronin, Senior Executive
312-847-1322
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.